Financial toxicity, part I: A new name for a growing problem

ONCOLOGY (United States)

Volumn 27, Issue 2, 2013, Pages

  Yousuf Zafar, S ^a   Abernethy, Amy P ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; COST OF ILLNESS; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL FEE; OUTPATIENT CARE; PATIENT CARE; PRESCRIPTION; UNSPECIFIED SIDE EFFECT;

EID: 84874590639     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Eagle D. The cost of cancer care: part I. Oncology (Williston Park). 2012;26:918-21,924.
2. Rettenmaier AJ. Healthcare financing and the cost of cancer care. Oncology (Williston Park). 2012;26:924,926.
3. de Souza JA. The cost of cancer care: there is more than one elephant in the room. Oncology (Williston Park). 2012;26:926-28.
4. Soni A. Top 10 most costly conditions among men and women, 2008: estimates for the U.S. civilian noninstitutionalized adult population, age 18 and older. Agency for Healthcare Research and Quality. Available from: http://meps.ahrq.gov/mepsweb/data_files/publications/st331/stat331.shtml. Accessed November 13, 2012.
5. Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010Äì2020. J Nat Cancer Inst. 2011;103:117-28.
6. Elkin EB, Bach PB. Cancers next frontier: addressing high and increasing costs. JAMA. 2010;303:1086-87.
7. Bach PB. Limits on Medicares ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626-33.
8. Gruber J. The role of consumer copayments for health care: lessons from the RAND health insurance experiment and beyond. Kaiser Family Foundation. Available from: http://www.kff.org/insurance/upload/7566.pdf. Accessed November 13, 2012.
9. Kaiser Family Foundation and Health Research & Trust. Employer health benefits, 2011 annual survey. Available from: http://ehbs.kff.org/pdf/2011/8225.pdf. Accessed October 5, 2011.
10. Kaiser Family Foundation. Distribution of covered workers facing different cost-sharing formulas for prescription drug benefits, 2000-2012. Available from: http://ehbs.kff.org/?page=charts&id=1&sn=8&ch=2676. Accessed November 13, 2012.
11. Bernard DSM, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29:2821-26.
12. Langa KM, Fendrick AM, Chernew ME, et al. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004;7:186-94.
13. Raborn ML, Pelletier EM, Smith DB, Reyes CM. Patient out-of-pocket payments for oral oncolytics: results from a 2009 us claims data analysis. J Oncol Pract. 2012;8:9s-15s.
14. Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012;30:1608-14.
15. Yabroff KR, Davis WW, Lamont EB, et al. Patient time costs associated with cancer care. J Nat Cancer Inst. 2007;99:14-23.
16. Hanratty B, Holland P, Jacoby A, Whitehead M. Financial stress and strain associated with terminal cancer--a review of the evidence. Palliat Med. 2007;21:595-607.
17. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29:2534-42.
18. Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7:46s-51s.
19. Markman M, Luce R. Impact of the cost of cancer treatment: an internet-based survey. J Oncol Pract. 2010;6:69-73.
20. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patients experience. Oncologist. 2013; In press.